Agenus (NASDAQ:AGEN) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Agenus (NASDAQ:AGEN) in a research report sent to investors on Wednesday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

Other research analysts have also recently issued reports about the company. HC Wainwright reaffirmed a buy rating and set a $160.00 price objective on shares of Agenus in a research report on Thursday, March 14th. B. Riley reduced their price objective on Agenus from $120.00 to $100.00 and set a buy rating for the company in a research report on Monday, March 18th.

Agenus Price Performance

AGEN stock opened at $5.40 on Wednesday. The stock has a market capitalization of $113.13 million, a P/E ratio of -0.38 and a beta of 1.26. The business has a 50-day moving average of $12.04 and a 200-day moving average of $14.35. Agenus has a fifty-two week low of $5.38 and a fifty-two week high of $42.60.

Agenus (NASDAQ:AGEN) last posted its quarterly earnings data on Thursday, March 14th. The biotechnology company reported ($2.60) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($2.20). The firm had revenue of $83.80 million during the quarter, compared to the consensus estimate of $54.21 million. Equities analysts expect that Agenus will post -8.2 EPS for the current year.

Insider Activity at Agenus

In related news, insider Garo H. Armen purchased 25,000 shares of Agenus stock in a transaction that occurred on Thursday, February 15th. The stock was purchased at an average cost of $13.00 per share, with a total value of $325,000.00. Following the completion of the transaction, the insider now owns 31,298 shares of the company’s stock, valued at approximately $406,874. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 4.80% of the company’s stock.

Institutional Trading of Agenus

Institutional investors and hedge funds have recently bought and sold shares of the business. U.S. Capital Wealth Advisors LLC bought a new stake in Agenus in the first quarter valued at approximately $25,000. Commonwealth Equity Services LLC bought a new stake in Agenus in the third quarter valued at approximately $26,000. Sei Investments Co. bought a new stake in Agenus in the first quarter valued at approximately $28,000. SG Americas Securities LLC bought a new stake in Agenus in the third quarter valued at approximately $36,000. Finally, Two Sigma Securities LLC raised its stake in Agenus by 116.9% in the second quarter. Two Sigma Securities LLC now owns 22,750 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 12,263 shares during the period. Institutional investors own 61.46% of the company’s stock.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.